Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?

Autor:	Martino M; Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli', Reggio Calabria, Italy., Gamberi B; Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy., Antonioli E; Hematology Department, Careggi Hospital, Florence, Italy., Aquino S; Hematology and Hematopoietic Stem Cell Transplantation Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Della Pepa R; Hematology Unit, Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy., Malerba L; Haematology and Haematopoietic Stem Cell Transplant Center, AST, Pesaro Urbino, Pesaro, Italy., Mangiacavalli S; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Pezzatti S; Department of Haematology, San Gerardo Hospital, Monza, MB, Italy., Bringhen S; SSD Clinical trial in oncoematologia e mieloma multiplo, Dipartimento di Oncologia, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy., Zamagni E; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
Jazyk:	angličtina
Zdroj:	Expert review of hematology [Expert Rev Hematol] 2024 Jul; Vol. 17 (7), pp. 375-390. Date of Electronic Publication: 2024 May 21.
DOI:	10.1080/17474086.2024.2357274
Abstrakt:	Introduction: Therapeutic strategies against multiple myeloma (MM) have evolved dramatically in recent decades, with unprecedent results in the treatment landscape, culminating in the recent incorporation of novel agents in the anti-myeloma armamentarium. Areas Covered: BCMA represents one of the most promising targets in MM and currently available immune approaches, either approved or under active investigation, are clearly showing their greater potential over standard regimens. In this context, immunotherapies based on chimeric antigen receptor (CAR)-engineered T-cells and bispecific antibodies (BsAbs) have taken center stage, being the ones that are yielding the most promising results in clinical trials. This review focuses on the current landscape of BsAbs and CAR-T, summarizing the latest advances and possible future developments. Expert Opinion: CAR-T and BsAbs anti-BCMA strategies represent breakthrough therapies against MM. However, their inclusion in clinical practice is almost feared, due to the associated limitations, some of which have been addressed here. Meanwhile, all the efforts should be focused on individualizing and choosing the most suitable candidates for each treatment and to understand how to combine, or sequence, these therapies to improve efficacy and minimize toxicity, especially for those patients with limited available treatment options.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu